

Myanmar Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Myanmar						
2. Grant number: 1821-MMR-12d-X / 16-MMR-08c-Y						
3. Date of Decision Letter: 21 December 2017						
4. Date of the Partnership Framework Agreement: 4 April 2014						
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine						
6. Vaccine type: Pneumococcal						
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID						
8. Programme duration¹: 2016 -2021						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)						
	2016-2017	2018	2019	2020	2021	Total ²
Programme Budget (US\$)	23,801,500 ³	8,733,000	9,716,000	10,107,000	10,188,000	62,545,500
10. Vaccine introduction grant (in US\$) / Product switch grant: A Vaccine Introduction Grant in the amount of US\$1,211,000 was previously disbursed on 8 February 2016 (US\$ 607,638) and 15 March 2016 (US\$ 603,362).						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴						
Type of supplies to be purchased with Gavi funds in each year	2016-2017	2018				
Number of Pneumococcal vaccines doses		2,596,600				
Annual Amounts (US\$)	23,801,500 ⁵	8,733,000				
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: Not applicable						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1821-MMR-12d-X-C</p> <p>According to the co-financing policy, Myanmar falls within the group Preparatory Transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>										
Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021						
Number of vaccine doses	236,800	294,400	343,800	404,800						
Number of AD syringes	233,200									
Number of re-constitution syringes										
Number of safety boxes	2,575									
Value of vaccine doses (US\$)	722,289									
Total co-financing payments (US\$) (including freight)	737,500	916,000	1,070,500	1,260,000						
<p>15. Operational support for campaigns: Not applicable</p>										
<p>16. Additional reporting requirements:</p> <table border="1"> <tr> <td>Reports and other information</td> <td>Due dates</td> </tr> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </table>					Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates									
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018									
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat									
<p>17. Financial clarifications: Not applicable</p>										
<p>18. Other conditions: Not applicable</p>										

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 21 December 2017